This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): triamcinolone acetonide
Description: Nasacort HFA is an intranasal steroid formulated with a hydrofluoroalkane (HFA) propellant and delivered as a fine, dry mist in a small volume pressurized metered dose.
Nasacort HFA was originally developed by Rhone-Poulenc Rorer.
Rhone and Hoechst
In January 1999, Rhone-Poulenc merged with Hoechst to form Aventis.
Aventis and Sanofi
In 2004, Aventis merged with Sanofi-Synthelabo to form Sanofi-Aventis.
Acton and Sanofi
In October 2011, Acton announced that it completed a licensing agreement with Sanofi U.S. for Nasacort HFA (triamcinolone acetonide) Nasal Aerosol for the treatment of nasal allergy symptoms. Under the agreement, Acton assumes the exclusive U.S. rights to develop and market Nasacort HFA.
Meda and Acton
In August 2013, Meda signed an agreement to acquire Acton including Aerospan. The purchase price for Acton amounts to 135 million USD. In addition, there is a milestone payment of 10 million USD and royalty based milestones. The acquisition is subject to customary closing conditions and the approval of the US competition authorities.
In October 2013, Meda...See full deal structure in Biomedtracker
Nasacort HFA News
Pink Sheet In Brief: Rhone-Poulenc Rorer Nasacort HFA
Pink Sheet Aventis CFC-Free Nasacort HFA Approved
Pink Sheet Aventis Nasacort HFA approved
Pink Sheet GSK Flovent HFA approved
Additional information available to subscribers only: